U.S. flag

An official website of the United States government

NC_000006.11:g.(32007026_32007132)_(32007983_32008182)del AND Congenital adrenal hyperplasia

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Apr 27, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003230923.1

Allele description [Variation Report for NC_000006.11:g.(32007026_32007132)_(32007983_32008182)del]

NC_000006.11:g.(32007026_32007132)_(32007983_32008182)del

Gene:
CYP21A2:cytochrome P450 family 21 subfamily A member 2 [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
6p21.33
Genomic location:
Chr6: 32007026 - 32008182 (on Assembly GRCh37)
Preferred name:
NC_000006.11:g.(32007026_32007132)_(32007983_32008182)del
HGVS:
NC_000006.11:g.(32007026_32007132)_(32007983_32008182)del

Condition(s)

Name:
Congenital adrenal hyperplasia (CAH)
Identifiers:
MONDO: MONDO:0018479; MedGen: C0001627; Human Phenotype Ontology: HP:0008258

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003929033Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Likely pathogenic
(Apr 27, 2023)
germlineclinical testing

PubMed (2)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Adrenal 21-hydroxylase gene mutations in Slovenian hyperandrogenic women: evaluation of corticotrophin stimulation and HLA polymorphisms in screening for carrier status.

Dolzan V, Prezelj J, Vidan-Jeras B, Breskvar K.

Eur J Endocrinol. 1999 Aug;141(2):132-9.

PubMed [citation]
PMID:
10427156

Genetic analysis and novel variation identification in Chinese patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Xia Y, Shi P, Gao S, Liu N, Zhang H, Kong X.

J Steroid Biochem Mol Biol. 2022 Sep;222:106156. doi: 10.1016/j.jsbmb.2022.106156. Epub 2022 Jul 23.

PubMed [citation]
PMID:
35882282

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV003929033.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (2)

Description

Variant summary: The variant identified by MLPA or other technology involves the deletion of exons 4-7 in the CYP21A2 gene. A presumed nomenclature of c.(447+1_448-1)_(939+1_940-1)del has been designated for the purposes of this classification. Although exact breakpoints of this CNV are not known, it is expected to result in a large in-frame deletion change in the CYP21A2 gene, a known mechanism of disease. Missense variants and in-frame deletions within this region have been reported as pathogenic by our lab and in ClinVar and are cited in association with Adrenal hyperplasia in HGMD. The frequency of this variant in the general population could not be determined as the technology used for structural variants in large population databases (gnomAD, Structural Variants database) could not detect variants of this type in CYP21A2. Additionally, allele frequency data in this gene may be confounded due to possible pseudogene overlap. Exon 4-7 deletion/conversions have been reported in the literature in individuals affected with Congenital Adrenal Hyperplasia (e.g., Xia_2022). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 10427156, 35882282). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Jun 10, 2023